Literature DB >> 27659357

Usefulness of chemoradiotherapy for inoperable gastric cancer.

T Taki1, Y Hoya1, A Watanabe1, T Nakayoshi1, T Okamoto1, H Sekine2, N Mitsumori2, K Yanaga3.   

Abstract

Introduction Radiotherapy is not commonly used for the treatment of gastric cancer in Japan, where surgery is the standard local treatment. We report the results of chemoradiotherapy in patients with advanced or recurrent gastric cancer which was deemed difficult to treat surgically. Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed. Results The tumour response to chemoradiotherapy was categorised as complete, partial, stable or progressive in 5, 9, 3, and 4 patients, respectively, with an overall response rate of 67%. No serious complications such as gastrointestinal perforation or bleeding occurred, and no cardiac, hepatic or renal dysfunction developed during the follow-up period. The mean survival time was 19.8 months (range, 3-51 months). One patient died of another disease, 18 died of primary cancer and the cause of death was unknown in 2 patients. Conclusions Chemoradiotherapy appears to be an effective treatment for localised gastric cancer without distant metastases, but further studies are needed to determine the indications for chemoradiotherapy and late adverse effects, as well as the chemotherapy regimens to be used.

Entities:  

Keywords:  Advanced gastric cancer; Chemo-radiation therapy; Non-curative resection; Recurrent gastric cancer

Mesh:

Substances:

Year:  2016        PMID: 27659357      PMCID: PMC5449671          DOI: 10.1308/rcsann.2016.0305

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  24 in total

1.  Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study.

Authors:  M Degiuli; M Sasako; A Ponti; T Soldati; F Danese; F Calvo
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  What is reasonable treatment for gastric adenocarcinoma?

Authors:  M Sasako
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

3.  The relative cellular radiosensitivity of 30 human in vitro cell lines of different histological type to high LET 62.5 MeV (p-->Be+) fast neutrons and 4 MeV photons.

Authors:  H M Warenius; R A Britten; J H Peacock
Journal:  Radiother Oncol       Date:  1994-01       Impact factor: 6.280

4.  Identification of human in vitro cell lines with greater intrinsic cellular radiosensitivity to 62.5 MeV (p-->Be+) neutrons than 4 MeV photons.

Authors:  H M Warenius; R A Britten; P G Browning; I E Morton; J H Peacock
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-03-01       Impact factor: 7.038

5.  Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma.

Authors:  Hironori Shigeoka; Haruhiko Imamoto; Yasumasa Nishimura; Taro Shimono; Hiroshi Furukawa; Hiroshi Imamura; Takushi Yasuda; Hitoshi Shiozaki
Journal:  World J Gastrointest Oncol       Date:  2010-06-15

6.  Small bowel perforation without tumor recurrence after radiotherapy for cervical carcinoma: report of seven cases.

Authors:  Hideomi Yamashita; Keiichi Nakagawa; Masao Tago; Hiroshi Igaki; Kenshirou Shiraishi; Naoki Nakamura; Nakashi Sasano; Sen Yamakawa; Kuni Ohtomo
Journal:  J Obstet Gynaecol Res       Date:  2006-04       Impact factor: 1.730

7.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

Review 8.  Clinical implications of heterogeneity of tumor response to radiation therapy.

Authors:  H Suit; S Skates; A Taghian; P Okunieff; J T Efird
Journal:  Radiother Oncol       Date:  1992-12       Impact factor: 6.280

9.  The management of gastric adenocarcinoma with postoperative chemoirradiation. A non-randomized comparison of oral UFT and 5-FU.

Authors:  Serdar Surenkok; Murat Beyzadeoglu; Kaan Oysul; Gokhan Ozyigit; Selmin Ataergin; Fikret Arpaci; Ahmet Ozet
Journal:  Tumori       Date:  2008 Jan-Feb

10.  Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer.

Authors:  M Degiuli; M Sasako; A Ponti; F Calvo
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more
  3 in total

1.  Clinical Efficacy of Acupuncture on Neoadjuvant Chemotherapy with Capecitabine plus Paclitaxel and Radiotherapy in Progressive Gastric Cancer.

Authors:  Xiaomei Miao; Hongying Wu; Yan Liu; Shu Zhang; Chaohui Li; Jie Hao
Journal:  J Oncol       Date:  2022-07-12       Impact factor: 4.501

Review 2.  Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?

Authors:  Jen-Hao Yeh; Yung-Sung Yeh; Hsiang-Lin Tsai; Ching-Wen Huang; Tsung-Kun Chang; Wei-Chih Su; Jaw-Yuan Wang
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

3.  A Case of Peritoneal Dissemination and Splenic Metastasis after Gastric Cancer Surgery That Could Be Controlled with Multidisciplinary Treatment.

Authors:  Nozomi Karakuchi; Senichiro Yanagawa; Daisuke Takei; Shinya Kodama; Yukio Takeshima; Kazuo Sumimoto
Journal:  Case Rep Oncol       Date:  2020-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.